155 related articles for article (PubMed ID: 35606403)
1. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59.
Son SW; Cho E; Cho H; Woo SR; Lee HJ; Oh SJ; Kim S; Kim JH; Chung EJ; Chung JY; Kim MG; Song KH; Kim TW
Sci Rep; 2022 May; 12(1):8652. PubMed ID: 35606403
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
3. HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
Song KH; Choi CH; Lee HJ; Oh SJ; Woo SR; Hong SO; Noh KH; Cho H; Chung EJ; Kim JH; Chung JY; Hewitt SM; Baek S; Lee KM; Yee C; Son M; Mao CP; Wu TC; Kim TW
Cancer Res; 2017 Sep; 77(18):5039-5053. PubMed ID: 28716899
[TBL] [Abstract][Full Text] [Related]
4. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.
Kim S; Cho H; Hong SO; Oh SJ; Lee HJ; Cho E; Woo SR; Song JS; Chung JY; Son SW; Yoon SM; Jeon YM; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Song KH; Kim TW
Autophagy; 2021 Aug; 17(8):1978-1997. PubMed ID: 32762616
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Woo SR; Lee HJ; Oh SJ; Kim S; Park SH; Lee J; Song KH; Kim TW
Biochem Biophys Res Commun; 2018 Sep; 503(3):1812-1818. PubMed ID: 30060952
[TBL] [Abstract][Full Text] [Related]
7. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
[TBL] [Abstract][Full Text] [Related]
8. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
[TBL] [Abstract][Full Text] [Related]
9. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
[TBL] [Abstract][Full Text] [Related]
10. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.
Donin N; Jurianz K; Ziporen L; Schultz S; Kirschfink M; Fishelson Z
Clin Exp Immunol; 2003 Feb; 131(2):254-63. PubMed ID: 12562385
[TBL] [Abstract][Full Text] [Related]
11. NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack.
Du Y; Teng X; Wang N; Zhang X; Chen J; Ding P; Qiao Q; Wang Q; Zhang L; Yang C; Yang Z; Chu Y; Du X; Zhou X; Hu W
J Biol Chem; 2014 Jan; 289(5):2711-24. PubMed ID: 24338025
[TBL] [Abstract][Full Text] [Related]
12. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
13. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
[TBL] [Abstract][Full Text] [Related]
14. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
[TBL] [Abstract][Full Text] [Related]
15. CD59: a promising target for tumor immunotherapy.
Zhang R; Liu Q; Liao Q; Zhao Y
Future Oncol; 2018 Apr; 14(8):781-791. PubMed ID: 29521526
[TBL] [Abstract][Full Text] [Related]
16. CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.
Chen J; Ding P; Li L; Gu H; Zhang X; Zhang L; Wang N; Gan L; Wang Q; Zhang W; Hu W
Stem Cell Reports; 2017 Jan; 8(1):140-151. PubMed ID: 28017655
[TBL] [Abstract][Full Text] [Related]
17. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
You T; Hu W; Ge X; Shen J; Qin X
Cell Mol Immunol; 2011 Mar; 8(2):157-63. PubMed ID: 21258360
[TBL] [Abstract][Full Text] [Related]
18. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
19. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Geller A; Yan J
Front Immunol; 2019; 10():1074. PubMed ID: 31164885
[TBL] [Abstract][Full Text] [Related]
20. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]